Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Prime Medicine (PRME) Net Income towards Common Stockholders (2021 - 2025)

Historic Net Income towards Common Stockholders for Prime Medicine (PRME) over the last 5 years, with Q3 2025 value amounting to -$50.6 million.

  • Prime Medicine's Net Income towards Common Stockholders rose 368.64% to -$50.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$197.3 million, marking a year-over-year increase of 999.32%. This contributed to the annual value of -$195.9 million for FY2024, which is 113.61% up from last year.
  • Per Prime Medicine's latest filing, its Net Income towards Common Stockholders stood at -$50.6 million for Q3 2025, which was up 368.64% from -$52.6 million recorded in Q2 2025.
  • In the past 5 years, Prime Medicine's Net Income towards Common Stockholders registered a high of -$22.8 million during Q3 2021, and its lowest value of -$69.3 million during Q4 2021.
  • Over the past 5 years, Prime Medicine's median Net Income towards Common Stockholders value was -$45.8 million (recorded in 2024), while the average stood at -$46.1 million.
  • In the last 5 years, Prime Medicine's Net Income towards Common Stockholders soared by 4139.56% in 2022 and then plummeted by 6169.42% in 2023.
  • Prime Medicine's Net Income towards Common Stockholders (Quarter) stood at -$69.3 million in 2021, then soared by 41.4% to -$40.6 million in 2022, then plummeted by 61.69% to -$65.6 million in 2023, then surged by 35.6% to -$42.3 million in 2024, then dropped by 19.65% to -$50.6 million in 2025.
  • Its Net Income towards Common Stockholders stands at -$50.6 million for Q3 2025, versus -$52.6 million for Q2 2025 and -$51.9 million for Q1 2025.